Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
108.19
(
0.67%
)
Bitcoin
76,977.96
(
-0.56%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 67956

Wednesday, 10/29/2008 9:40:49 PM

Wednesday, October 29, 2008 9:40:49 PM

Post# of 257580
GSK had an HCV polymerase inhibitor in phase-1 that was dropped in 2007.

>Wonder if they would buy vrtx?<

The $57M GSK is paying to get GNLB is barely more than round-off error.

GSK recently discontinued its share-buyback program to facilitate the financing of one or more large acquisitions.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today